| Project Title | Drug Use Following Genetic Testing Among Patients with Cancer |
| Date Posted | Wednesday, May 10, 2017 |
| Project ID | cder_mpl1r_wp021-23_nsdp_v01 |
| Status | Complete |
| Deliverables | |
| Description | This project contains three reports. Report 1 contains estimates of drug use among patients with a prior genetic test and/or relevant cancer diagnosis. Report 2 contains estimated distribution of baseline covariates among members receiving various genetic tests: KRAS, BRAF, EGFR, BCR-ABL, and BRCA. Report 3 contains estimates of drug initiation following genetic testing among patients with relevant cancers.The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2013 to December 31, 2015. The request was distributed to 14 Data Partners on June 17, 2016. |
| Medical Product | BCR-ABL BRAF BRCA KRAS afatinib dimaleate bosutinib cetuximab cobimetinib fumarate dabrafenib mesylate dasatinib erlotinib HCL estimated glomerular filtration rate (eGFR) gefitinib imatinib mesylate nilotinib HCL olaparib osimertinib mesylate panitumumab ponatinib HCL trametinib dimethyl sulfoxide vemurafenib |
| Health Outcome | cancer |
| Population / Cohort | All individuals |
| Time Period | January 1, 2013 - December 31, 2015 |
| Assessment Type | Exploratory Analyses |
| Study Type | Modular Program |
| Data Sources | Sentinel Distributed Database (SDD) |
| FDA Center | CDER |
